Literature DB >> 16998887

Serum antibody decay in adults following natural respiratory syncytial virus infection.

Ann R Falsey1, Harjot K Singh, Edward E Walsh.   

Abstract

Serum antibody decay following RSV infection in adults was examined to evaluate the durability of the immune response. Twenty subjects with RSV infection and 10 subjects who remained RSV uninfected had blood samples obtained over 16-25 months analyzed by microneutralization assay and enzyme immunoassay. The mean titers of infected subjects rose approximately eightfold post-infection. The mean rate of antibody decline was -0.20 log 2 titer per month which led to a > or =fourfold drop in titer in 75% of subjects at 1 year. In contrast, titers of uninfected subjects were relatively stable. The partial immunity resulting from a boost in serum antibody following natural RSV infection in adults appears to be short lived.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16998887     DOI: 10.1002/jmv.20724

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  44 in total

1.  Effects of aging on the adaptive immune response to respiratory virus infections.

Authors:  Ross B Fulton; Steven M Varga
Journal:  Aging health       Date:  2009-12-01

2.  Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults.

Authors:  F Eun-Hyung Lee; Ann R Falsey; Jessica L Halliley; Iñaki Sanz; Edward E Walsh
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

3.  Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination.

Authors:  Hongjing Gu; Tieling Li; Lina Han; Ping Zhu; Peirui Zhang; Shaogeng Zhang; Sujing Sun; Yueqiang Duan; Li Xing; Zhongpeng Zhao; Chengcai Lai; Bohai Wen; Xiliang Wang; PengHui Yang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

5.  Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

Authors:  John P DeVincenzo; Tom Wilkinson; Akshay Vaishnaw; Jeff Cehelsky; Rachel Meyers; Saraswathy Nochur; Lisa Harrison; Patricia Meeking; Alex Mann; Elizabeth Moane; John Oxford; Rajat Pareek; Ryves Moore; Ed Walsh; Robert Studholme; Preston Dorsett; Rene Alvarez; Robert Lambkin-Williams
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

Review 6.  Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns.

Authors:  Nicole Baumgarth; Janko Nikolich-Žugich; F Eun-Hyung Lee; Deepta Bhattacharya
Journal:  J Immunol       Date:  2020-09-04       Impact factor: 5.422

7.  A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.

Authors:  John DeVincenzo; Robert Lambkin-Williams; Tom Wilkinson; Jeffrey Cehelsky; Sara Nochur; Edward Walsh; Rachel Meyers; Jared Gollob; Akshay Vaishnaw
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

8.  Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein.

Authors:  Anu Cherukuri; Kathryn Patton; Robert A Gasser; Fengrong Zuo; Jennifer Woo; Mark T Esser; Roderick S Tang
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

9.  Viral shedding and immune responses to respiratory syncytial virus infection in older adults.

Authors:  Edward E Walsh; Derick R Peterson; Aja E Kalkanoglu; Frances Eun-Hyung Lee; Ann R Falsey
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

10.  Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.

Authors:  Ivy Widjaja; Oliver Wicht; Willem Luytjes; Kees Leenhouts; Peter J M Rottier; Frank J M van Kuppeveld; Bert Jan Haijema; Cornelis A M de Haan
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.